A clinical trial developed by a Taiwanese research team has offered a glimmer of hope for patients of neuroblastoma, a malignant cancer that appears in early childhood, a press statement released by the Academia Sinica said.
The research team at the research institute has proven that a combination of anti-cancer monoclonal antibodies (mAbs) with cytokines (natural hormones that help the immune system) is an effective anti-cancer therapy.
The new immunotherapy treatment pioneered by the research team, headed by Alice Yu (陳鈴津), deputy director of Academia Sinica’s Genomics Research Center, is the first study that confirms that immunotherapy is effective in improving cure rates for this childhood cancer, the statement said.
Yu, a pediatrician, has been working on the therapy for more than 20 years. She completed the Phase I and Phase II trials of this antibody at the University of California in San Diego.
The latest Phase III trial was sponsored by the US-based Children’s Oncology Group (COG), a cancer research organization, and the National Cancer Institute of the National Institutes of Health in the US. The latest results included children with neuroblastoma from many parts of the world.
Neuroblastoma is a malignant cancer occurring in early childhood in which the cancer cells arise from the nerve cells in the neck, chest or abdomen.
It is the most common cancer diagnosed in the first year of life and is responsible for 15 percent of cancer-related deaths in children.
The Phase III study showed that children with high risk neuroblastoma who received the new antibody-based immunotherapy (chimeric anti-GD2 antibody ch14.18) have a 20 percent better chance of living free of cancer, a significantly improved cure rate.
So far, Yu said, all US Federal Drug Administration (FDA) approved therapeutic anti-cancer mAbs or vaccines are directed against protein or glycoprotein antigens.
“The Phase III clinical trial is the first mAb targeting a glycolipid that has been shown to be effective,” Yu said.
More importantly, she added, this is the first study that proves that immunotherapy is effective in improving cure rates for this childhood cancer and her team is now focusing on making sure immunotherapy can be available to all children with this disease and on improving results.
COG Chairman Gregory Reaman stated in a press release that the clinical benefit of this approach against the notoriously stubborn child cancer is extraordinary and that the COG is anxious to continue its investigation to better define the toxicities and confirm its satisfactory risk-benefit ratio.
“We are hopeful that that this further study will result in commercialization and FDA approval and licensing of this experimental immunotherapeutic agent so that it can be made readily available as standard therapy to all children with this dreaded disease,” Reaman said in the statement.
Conventional treatment for the disease includes surgery, intensive chemotherapy with stem cell rescue (in which patients’ stem cells removed before treatment are returned after chemotherapy to repopulate the blood and immune system) and radiation therapy.
Despite these aggressive measures, only 30 percent of patients survive.
The immunotherapy evaluated in this study targets a specific glycolipid (sugar and fat) molecule on neuroblastoma cells called GD2 — which inhibits the immune system from attacking cancer cells — with an antibody called ch14.18.
This antibody binds to GD2 and provokes an attack by different types of immune cells against the cancer.
In her study, Yu and her colleagues compared the two-year event-free survival rate (the ratio of patients who were still alive and did not experience a recurrence) of 113 neuroblastoma patients who received the standard treatment (retinoic acid) plus the newly developed immunotherapy with 113 similar patients who only received the standard treatment.
The event-free survival rate for the immunotherapy group was 66 percent, compared to 46 percent for the standard treatment group. The most common side effects in the immunotherapy group were pain, vascular leak syndrome and allergic reactions.
As the study is the first effective immunotherapy reported for the disease and the first improvement on neuroblastoma cure rates of the last 10 years, it has drawn worldwide attention and was reported in USA Today and by US television network CBS.
It is estimated that it will take at least another two years to get FDA approval for the therapy.
DEEPER REVIEW: After receiving 19 hospital reports of suspected food poisoning, the Taipei Department of Health applied for an epidemiological investigation A buffet restaurant in Taipei’s Xinyi District (信義) is to be fined NT$3 million (US$91,233) after it remained opened despite an order to suspend operations following reports that 32 people had been treated for suspected food poisoning, the Taipei Department of Health said yesterday. The health department said it on Tuesday received reports from hospitals of people who had suspected food poisoning symptoms, including nausea, vomiting, stomach pain and diarrhea, after they ate at an INPARADISE (饗饗) branch in Breeze Xinyi on Sunday and Monday. As more than six people who ate at the restaurant sought medical treatment, the department ordered the
A strong continental cold air mass and abundant moisture bringing snow to mountains 3,000m and higher over the past few days are a reminder that more than 60 years ago Taiwan had an outdoor ski resort that gradually disappeared in part due to climate change. On Oct. 24, 2021, the National Development Council posted a series of photographs on Facebook recounting the days when Taiwan had a ski resort on Hehuanshan (合歡山) in Nantou County. More than 60 years ago, when developing a branch of the Central Cross-Island Highway, the government discovered that Hehuanshan, with an elevation of more than 3,100m,
Taiwan’s population last year shrank further and births continued to decline to a yearly low, the Ministry of the Interior announced today. The ministry published the 2024 population demographics statistics, highlighting record lows in births and bringing attention to Taiwan’s aging population. The nation’s population last year stood at 23,400,220, a decrease of 20,222 individuals compared to 2023. Last year, there were 134,856 births, representing a crude birth rate of 5.76 per 1,000 people, a slight decline from 2023’s 135,571 births and 5.81 crude birth rate. This decrease of 715 births resulted in a new record low per the ministry’s data. Since 2016, which saw
SECURITY: To protect the nation’s Internet cables, the navy should use buoys marking waters within 50m of them as a restricted zone, a former navy squadron commander said A Chinese cargo ship repeatedly intruded into Taiwan’s contiguous and sovereign waters for three months before allegedly damaging an undersea Internet cable off Kaohsiung, a Liberty Times (sister paper of the Taipei Times) investigation revealed. Using publicly available information, the Liberty Times was able to reconstruct the Shunxing-39’s movements near Taiwan since Double Ten National Day last year. Taiwanese officials did not respond to the freighter’s intrusions until Friday last week, when the ship, registered in Cameroon and Tanzania, turned off its automatic identification system shortly before damage was inflicted to a key cable linking Taiwan to the rest of
RSS